SARS-CoV2 感染对哺乳和母乳喂养的影响的疫苗接种和治疗选择。

Vaccination and treatment options for SARS-CoV2 infection affecting lactation and breastfeeding.

机构信息

Department of Obstetrics and Gynecology, University of California, Davis, 4860 Y Street, Suite 2500, Sacramento, CA, 95817, USA.

Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, School of Medicine, UC Davis Children's Hospital, 2315 Stockton Blvd, Sacramento, CA, 95817, USA.

出版信息

Semin Fetal Neonatal Med. 2023 Feb;28(1):101425. doi: 10.1016/j.siny.2023.101425. Epub 2023 Feb 13.

DOI:10.1016/j.siny.2023.101425

PMID:36804921

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9924042/

Abstract

The COVID-19 pandemic has posed considerable challenges to the health of lactating individuals. Vaccination remains one of the most important strategies for prevention of moderate to severe COVID-19 infection and is associated with protective benefits for lactating individuals and their breastfed infants with overall mild side effects. The current recommendations for COVID-19 treatment in lactating individuals includes remdesivir and dexamethasone for hospitalized patients and Paxlovid® (nirmatrelavir + ritonavir) as outpatient treatment in those with mild disease. As the pandemic continues to evolve with new COVID-19 variants, alternative therapeutic options are potentially needed, and it is critical to include lactating individuals in research to evaluate the safety and efficacy of COVID-19 treatment options in this population.

摘要

COVID-19 大流行给哺乳期个体的健康带来了相当大的挑战。接种疫苗仍然是预防中度至重度 COVID-19 感染的最重要策略之一，并且与保护哺乳期个体及其母乳喂养婴儿相关，总体副作用较轻。目前针对哺乳期个体的 COVID-19 治疗建议包括住院患者使用瑞德西韦和地塞米松，以及轻症患者使用帕罗维德（nirmatrelavir +ritonavir）作为门诊治疗。随着新的 COVID-19 变异株的不断出现，可能需要替代治疗方案，因此必须让哺乳期个体参与研究，以评估该人群 COVID-19 治疗方案的安全性和有效性。